Beijing Tongren Hospital

This study tests a drug called orelabrutinib, taken alone or with another antibody, in people with untreated marginal zone lymphoma. The goal is to see how well the treatment shrinks or controls the cancer. About 88 participants will receive the drug for 6 cycles, and doctors wil…

This study tests a drug called zanubrutinib combined with standard chemotherapy for people newly diagnosed with a fast-growing lymphoma (DLBCL) that has high-risk features. About 50 participants will receive the combination to see if it improves remission rates. The goal is to fi…

This study tests a combination of three drugs (pomalidomide, an anti-PD-1 antibody, and selinexor) in people whose primary central nervous system lymphoma has come back or stopped responding to treatment. The goal is to see if this drug cocktail can shrink tumors and improve surv…

This study tests two types of special glasses lenses designed to slow the progression of nearsightedness (myopia) in children aged 6 to 14. About 120 children will wear the lenses daily for one year and have regular eye exams. The goal is to see if the lenses reduce how much the …

This study tests a new combination of drugs (MEPL-G) for people with a rare and aggressive lymphoma (NK/T-cell lymphoma) that has triggered a dangerous overreaction of the immune system called HLH. The goal is to control both the cancer and the immune chaos quickly, improving sur…

This early-stage study tests two drugs (finotonlimab and stapokibart) together in 10 adults with recurrent or metastatic head and neck squamous cell carcinoma that worsened after standard treatment. The main goals are to see if the combination is safe and whether it can shrink tu…

This study tests a new antibody drug for people whose seasonal allergies are not well controlled by standard treatments. The drug targets a protein involved in allergic inflammation. About 120 adults will receive either the drug or a placebo, and researchers will track changes in…

This study looks at how high blood pressure, diabetes, and high cholesterol change the tiny blood vessels in the retina (the back of the eye). Researchers will use a special, non-invasive scan called OCTA to measure these changes over five years. The goal is to see if eye vessel …